|Report title||PDF Download||Date Published||company_hfilter|
|MiMedx – MiMedx’s (NASDAQ:MDXG) employment of kickback & bribery scheme inducers makes it uninvestable.||Download||September 20, 2020||mimedx|
|Ebix – FOIA response confirms enforcement investigation||Download||July 1, 2019||ebix|
|Viceroy Members Commence Litigation Against MiMedx and Parker H Petit||Download||June 17, 2019||mimedx|
|Ebix – Goodwill Hunting||Download||December 3, 2018||ebix|
|MiMedx – Open Letter to MiMedx||Download||October 15, 2018||mimedx|
|MiMedx – Filling In The Blanks||Download||June 25, 2018||mimedx|
|MiMedx – No Comment||Download||June 8, 2018||mimedx|
|MiMedx – Viceroy’s MiMedx Greatest Hits||Download||May 11, 2018||mimedx|
|MiMedx – The curious case of Mad River Community Hospital||Download||February 22, 2018||mimedx|
|MiMedx – As promised: MiMedx’s concealed documents||Download||December 28, 2017||mimedx|
|MiMedx – Viceroy activates “The Honeypot”: Parker H. Petit & MiMedx caught red-handed||Download||December 14, 2017||mimedx|
|MiMedx – MiMedx continue to consciously mislead investors, defame Viceroy and Marc Cohodes||Download||December 13, 2017||mimedx|
|MiMedx – Viceroy release MiMedx EOB emails||Download||December 11, 2017||mimedx|
|MiMedx – MiMedx now under investigation by DOJ enforcement & VA||Download||November 30, 2017||mimedx|
|MiMedx – Caught red-handed circumventing VA regulations||Download||November 21, 2017||mimedx|
|MiMedx – Vendors soliciting up-coding of Medicare incentives.||Download||November 16, 2017||mimedx|
|MiMedx – Emails with the VA & new Whistleblower counter-claims||Download||November 8, 2017||mimedx|
|MiMedx – Halloween Special: Viceroy evidence more PODs and channel stuffing of deceased doctors.||Download||October 31, 2017||mimedx|
|MiMedx – “The same thing happened at Matria”||Download||October 30, 2017||mimedx|
|MiMedx – Palmer-geddon||Download||October 27, 2017||mimedx|
|MiMedx – 2016 Ortho Sales Reports: Read ‘em & weep||Download||October 26, 2017||mimedx|
|MiMedx – Up Schmidt Creek||Download||October 20, 2017||mimedx|
|MiMedx – More physician owned distributors; MiMedx may not wish to address its investors but it will have to answer the regulators||Download||October 17, 2017||mimedx|
|MiMedx – Bankruptcy & DOJ/FBI indictments of Physician-Owned Medical Center inconvenienced MiMedx CPM channel stuffing program||Download||October 13, 2017||mimedx|
|MiMedx – More whistleblowers come forward with details of MiMedx sales scheme||Download||October 10, 2017||mimedx|
|MiMedx – Ex-employees blow the lid on MiMedx sales scheme||Download||October 5, 2017||mimedx|
|MiMedx – How are MiMedx making their numbers?||Download||October 4, 2017||mimedx|
|MiMedx – MiMedx’s selective non-compete litigation & questionable disclosures||Download||October 3, 2017||mimedx|
|MiMedx – Channel-Stuffing: Hard Evidence||Download||October 2, 2017||mimedx|
|MiMedx – Part 2 – The same old story; Mimedx’s response is typical of companies trying to cover their tracks and is unacceptable.||Download||September 26, 2017||mimedx|
Viceroy Research LLC are an investigative financial research group registered in Delaware, USA.
Our research reports have been prepared for educational purposes only and expresses our opinions. Our reports and any statements made in connection with them are the authors’ opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.
To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stocks covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented “as is,” without warranty of any kind – whether express or implied.
In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using our research reports, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.
This website, all documents contained herein or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.
Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.
You should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.
The authors may continue transacting directly and/or indirectly in the securities of issuers covered herein for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.